Tuberous sclerosis treatment

作者: Ingrid Elmroth , Michael Stumm , Heidi Lane , William Berg , William Sellers

DOI:

关键词:

摘要: PROBLEM TO BE SOLVED: To provide a compound, etc. for the use of treating and preventing neurocutaneous disorders, like mediated via tuberous sclerosis complex, e.g., neurofibromatosis type 1.SOLUTION: There are provided rapamycin derivative formula I [wherein, Ris CHor 3-6C alkynyl; H, -CH-CH-OH or -CH-CH-O-(1-8C) alkyl, -CH-CH-O-CH-CH; X is =O, (H, H) OH), wherein when =O CH, not H] provided, pharmaceutical composition containing same.

参考文章(19)
David E. Weinstein, Scott Wadsworth, Raymond Birge, John Siekierka, Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue ,(2002)
Gabriele I. Kirchner, Michael Winkler, Lueke Mueller, Christian Vidal, Wolfgang Jacobsen, Anke Franzke, Siegfried Wagner, Stefan Blick, Michael P. Manns, Karl-Friedrich Sewing, Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD British Journal of Clinical Pharmacology. ,vol. 50, pp. 449- 454 ,(2000) , 10.1046/J.1365-2125.2000.00293.X
Baldwin C. Mak, Raymond S. Yeung, The tuberous sclerosis complex genes in tumor development. Cancer Investigation. ,vol. 22, pp. 588- 603 ,(2004) , 10.1081/CNV-200027144
Ralf Wienecke, Ingrid Fackler, Ulrich Linsenmaier, Karin Mayer, Thomas Licht, Matthias Kretzler, Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex American Journal of Kidney Diseases. ,vol. 48, pp. e27- e29 ,(2006) , 10.1053/J.AJKD.2006.05.018
P Neuhaus, mTOR inhibitors: An overview Liver Transplantation. ,vol. 7, pp. 473- 484 ,(2001) , 10.1053/JLTS.2001.24645